semaglutide type 1 diabetes automated insulin delivery randomized trial 2025 ADA Recap: Improving Lives semaglutide type 1 diabetes automated

As if you had broken the key in the lock, the door no longer opens

Nevertheless, in a systematic review and network meta-analysis of controlled studies reporting the risk of all-cause mortality, CV mortality, or myocardial infarction (MI), later-generation SUs such as glimepiride and gliclazide were associated with a significantly lower risk of all-cause and CV mortality compared to glibenclamide [59], whereas glibenclamide was associated with a lower risk of sudden cardiac arrest and ventricular arrhythmias, at least when compared to glipizide, and may be associated with a reduced risk of ventricular tachycardia and isolated ventricular premature complexes [60]

All the text is legible, with all pages included

20:e12884